<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Stone, J. R. | THE MILLER LAB</title>
    <link>/authors/stone-j.-r./</link>
      <atom:link href="/authors/stone-j.-r./index.xml" rel="self" type="application/rss+xml" />
    <description>Stone, J. R.</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Fri, 08 Sep 2017 00:00:00 +0000</lastBuildDate>
    <image>
      <url>img/map[gravatar:%!s(bool=false) shape:circle]</url>
      <title>Stone, J. R.</title>
      <link>/authors/stone-j.-r./</link>
    </image>
    
    <item>
      <title>A Complete Response in cSCC with Ipi/Nivo</title>
      <link>/publication/cr-ipi-nivo-scc/</link>
      <pubDate>Fri, 08 Sep 2017 00:00:00 +0000</pubDate>
      <guid>/publication/cr-ipi-nivo-scc/</guid>
      <description>&lt;h1 id=&#34;abstract&#34;&gt;Abstract:&lt;/h1&gt;
&lt;p&gt;Although most cases of metastatic cutaneous Squamous Cell Carcinoma mCSCC can be cured with local therapy, up to 8,000 deaths occur each year. With no US Food and Drug Administration-approved options available for mcSCC, common approaches include platinum- based chemotherapy and off-label cetuximab. These strategies lack durability, and overall survival for mcSCC is only 10.9 months. Here we report a complete pathologic response after 4 cycles of nivolumab and the antieCTLA-4 antibody, ipilimumab, in a patient with mCSCC.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
